Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.44 |
| ▸ | PPARG | P37231 | 7/20 | 0.44 |
| ▸ | PPARD | Q03181 | 4/20 | 0.41 |
| ▸ | ESR1 | P03372 | 8/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2000748 | 0.85 | GRM2 (0.48) | PPARAPPARGPPARDESR1ESR2 | |
| SCHEMBL5208846 | 0.83 | PPARG (0.44) | PPARAPPARGPPARDKDM4EALDH1A1 | |
| SCHEMBL7039212 | 0.83 | PPARA (0.38) | PPARAPPARGPPARDESR1ESR2 | |
| SCHEMBL7039280 | 0.83 | PPARA (0.42) | PPARAPPARGPPARDKDM4EGAA | |
| SCHEMBL1400579 | 0.83 | PPARD (0.39) | PPARAPPARGPPARDESR1ESR2 | |
| SCHEMBL7044510 | 0.81 | ALOX5 (0.39) | PPARAPPARGPPARDKDM4EALDH1A1 | |
| SCHEMBL5210820 | 0.81 | PPARA (0.43) | PPARAPPARGPPARD | |
| SCHEMBL1941899 | 0.80 | ALDH1A1 (0.34) | PPARAPPARGPPARDESR1ESR2 | |
| SCHEMBL5210388 | 0.79 | PPARA (0.41) | PPARAPPARGPPARDGRM2 | |
| SCHEMBL7042123 | 0.79 | PPARA (0.48) | PPARAPPARGPPARDESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960417-B2 | Such as 1-(2,2-dimethylpropyl)-4-propyl-5-{4-[4-(1H-tetrazol-5-yl)phenoxy]butoxy}-1H-indole; neurological and psychiatric disorders | MERCK SHARP & DOHME CORP. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7495020-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495020-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495020-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | MERCK SHARP & DOHME CORP. | 2008-07-24 | — | — | US | disclosed |
| EP-1855670-A2 | BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006091496-A2 | BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| US-7091230-B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060122242-A1 | 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2006-06-08 | — | — | US | disclosed |
| EP-1366012-A4 | 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS | MERCK & CO INC (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040092596-A1 | 2-Aryloxy-2arylalkanoic acids for diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2004-05-13 | — | — | US | disclosed |
| EP-1366012-A2 | 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS | Merck & Co., Inc. (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-0882029-B1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK & CO INC (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002064094-A2 | 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| US-6090836-A | DIETETICS; ADJUSTMENT OF TRIGLYCERIDE CONCENTRATION | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0882029-A1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | Merck & Co., Inc. (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997028137-A1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | GRM2, GRM3, GRIK2 | PPARA 222/4885PPARG 98/4885PPARD 108/4885 |
| US-20060122242-A1 | 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885PPARD 3/4885 |
| US-20040092596-A1 | 2-Aryloxy-2arylalkanoic acids for diabetes and lipid disorders | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.